1591 related articles for article (PubMed ID: 26873684)
1. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
[TBL] [Abstract][Full Text] [Related]
2. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
[TBL] [Abstract][Full Text] [Related]
5. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy.
Francia P; Adduci C; Semprini L; Palano F; Santini D; Musumeci B; Santolamazza C; Volpe M; Autore C
J Cardiovasc Electrophysiol; 2017 Jan; 28(1):103-108. PubMed ID: 27862589
[TBL] [Abstract][Full Text] [Related]
7. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
[TBL] [Abstract][Full Text] [Related]
8. Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy.
Srinivasan NT; Patel KH; Qamar K; Taylor A; Bacà M; Providência R; Tome-Esteban M; Elliott PM; Lambiase PD
Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408651
[TBL] [Abstract][Full Text] [Related]
9. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
Lambiase PD; Gold MR; Hood M; Boersma L; Theuns DAMJ; Burke MC; Weiss R; Russo AM; Kääb S; Knight BP
Heart Rhythm; 2016 May; 13(5):1066-1074. PubMed ID: 26767422
[TBL] [Abstract][Full Text] [Related]
11. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
[TBL] [Abstract][Full Text] [Related]
12. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.
Guo L; Zhang M; Hu M; Wang B; Wang J; Zuo L; Yang W; Liu B; Liu L
Heart Vessels; 2019 May; 34(5):851-859. PubMed ID: 30465278
[TBL] [Abstract][Full Text] [Related]
14. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
15. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
16. Post-shock oversensing by a subcutaneous defibrillator resulting in inappropriate withholding of post-shock bradycardia pacing.
Maass AH; Van Gelder IC
Europace; 2014 Jul; 16(7):1032. PubMed ID: 24792457
[No Abstract] [Full Text] [Related]
17. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
Rudic B; Tülümen E; Berlin V; Röger S; Stach K; Liebe V; El-Battrawy I; Dösch C; Papavassiliu T; Akin I; Borggrefe M; Kuschyk J
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042423
[TBL] [Abstract][Full Text] [Related]
18. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
Rowin EJ; Burrows A; Madias C; Estes NAM; Link MS; Maron MS; Maron BJ
Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008123. PubMed ID: 32897759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
